TAPIMMUNE INC COM USD0.001 (TPIV)

0.43
OTC Markets
Prev Close 0.42
Day Low/High 0.42 / 0.43
52 Wk Low/High 0.31 / 0.97
Exchange OTC Markets
Shares Outstanding 71.03B
Market Cap 29.83M
Div & Yield N.A. (N.A)

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

TapImmune Appoints Frederick G. Wasserman To Its Board Of Directors

Accomplished Financial Director & CFO of Public Companies

U.S. Food & Drug Administration Grants Orphan Drug Designation To TapImmune's TPIV 200 In The Treatment Of Ovarian Cancer

Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I trial

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters To Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville

TapImmune Inc To Present At The SeeThruEquities Fall

MicroCap Investors Conference on September 10, 2015

TapImmune Completes Transfer Of IND From The Mayo Clinic

Significant Milestone Marks The Next Major Step in Beginning Phase 2 Trials in Cancer Using The Folate Receptor Alpha Peptide Vaccine Technology

TapImmune Appoints John N. Bonfiglio, Ph.D., To Its Board Of Directors

Accomplished Biotech CEO is currently a Strategic Advisor to TapImmune

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A Folate Receptor Alpha Vaccine For Multiple Cancer Indications

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

TapImmune Reports Robust Immune Responses Generated In 19 Of 20 Evaluable HER2/neu Breast Cancer Patients

Phase I Trial analyses shows safety and positive immune response data